Evidence-based safety information about medication, vaccine, chemical and radiological exposures in pregnancy

Treatment of COVID-19 in pregnancy

Read our monograph on COVID-19 treatments in pregnancy for the most up-to-date information on COVID-19 treatment.

COVID-19 Antivirals Pregnancy Registry

We are gathering information about the use of COVID-19 antivirals in pregnancy (UKHSA/MHRA collaboration). Please report into our registry.

COVID-19 vaccination in pregnancy

Read our monograph on the use of non-live vaccines (including COVID-19) during pregnancy.

Use of therapeutic amfetamines in pregnancy

Due to the considerable number of enquiries we have received about treating ADHD in pregnancy with lisdexamfetamine, we have published a summary of the available safety evidence for therapeutic amfetamines.

Use of methylphenidate in pregnancy

Our latest publication – We applied a meta-analysis approach to summarise the published evidence on cardiac malformation risk after first trimester methylphenidate use. Read the paper here. Also see our recently updated systematic evidence review on the use of methylphenidate in pregnancy.

High-dose folic acid in WWE and cancer risk

In response to the results of a large multi-national study investigating cancer risks in the offspring of women with epilepsy who used high-dose folic acid in pregnancy we have prepared a position statement providing our interpretation of the evidence. High-dose folic acid use in women with epilepsy in pregnancy and childhood cancer risk – UKTIS.

Link to the study – Cancer Risk in Children of Mothers With Epilepsy and High-Dose Folic Acid Use During Pregnancy

Latest papers from the field of teratology

European Society for Medical Oncology publish expert consensus recommendations on the management of breast cancer during pregnancy

Consensus recommendations on the management of depressive disorders in pregnancy

Case series of pregnancy and fetal outcomes following maternal use of long-acting injectable antipsychotics during pregnancy

Pregnancy and fetal outcomes following maternal use of glatiramer acetate

Malformation risks following first trimester COVID-19 vaccination

Congenital malformation risks following integrase inhibitor use in pregnancy

UKTIS on Twitter

Who are UKTIS?

UKTIS is commissioned by the UK Health Security Agency (UKHSA) and hosted by The Newcastle upon Tyne Hospitals NHS Foundation Trust to perform national surveillance of known and emerging human teratogens.

Information collected by UKTIS is recognised by the Caldicott Advisory Panel of UKHSA.